Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05069896 · ClinicalTrials.gov registry record · Phase 1
A Study to Compare Two Formulations of Mirikizumab (LY3074828) in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 237
- Enrollment target
NCT05069896 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 237 participants.
The verdict
NCT05069896, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 237 participants
- Enrollment target
Study Summary
The main purpose of this study is to compare the amount of mirikizumab that gets into the blood stream and how long it takes the body to get rid of it, when given as a solution formulation via manual prefilled syringe or autoinjector. The information about any adverse effects experienced will be collected and the tolerability of mirikizumab will also be evaluated. Screening is required within 28 days prior to the enrolment. For each participant, the total duration of the clinical trial will be about 17 weeks including screening.
Interventions
- DRUG Mirikizumab Prefilled Syringe
- DRUG Mirikizumab Autoinjector
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 237 participants |
| Start Date | 2021-10-05 |
| Est. Completion | 2022-06-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05069896
The ClinicalTrials.gov registry entry for NCT05069896 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 237 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Mirikizumab Prefilled Syringe is the first listed.
NCT05069896 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05069896 about?
NCT05069896 is a clinical study titled "A Study to Compare Two Formulations of Mirikizumab (LY3074828) in Healthy Participants". The main purpose of this study is to compare the amount of mirikizumab that gets into the blood stream and how long it takes the body to get rid of it, when given as a solution formulation via manual prefilled syringe or autoinjector. The information about any adverse effects experienced will be col...
What is the current status of trial NCT05069896?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 237 participants. The study started on 2021-10-05. Estimated completion is 2022-06-22.
What interventions are being tested in trial NCT05069896?
The interventions under investigation include: Mirikizumab Prefilled Syringe (DRUG), Mirikizumab Autoinjector (DRUG).
Who is sponsoring clinical trial NCT05069896?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.